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Background: Life Sciences research, enhancing the occurrence of innovation, is able to impact clinical 
decision-making, both at diagnosis and therapy. Indeed, starting from the knowledge of specific needs and 
of technical-scientific demands, researchers can conceive and experiment innovative solutions. Despite these 
strengths, transferring research to the market in Life Sciences shows considerable criticalities. The aim of 
this paper is to provide concrete evidences on the processes of technology transfer based on the exploitation 
of the results obtained by KronosDNAsrl, an academic spin-off focused on reproductive medicine.
Methods: Different tools were used to evaluate the technical feasibility (validation of the results obtained 
with the prototype) and to manage the technology transfer process of One4Two®.
Results: The different analyses we carried out showed the feasibility of the proposed solution. As a result, 
the One4Two® prototype has been developed and validated.
Conclusions: Here, we provide a strength of evidences on how knowledge obtained by translational 
research on “bench” can be used to be transferred to the market on “benchmark” enabling innovation in 
Laboratory Medicine. In addition, the model described for One4Two® can be easily transferred to other 
products.
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Introduction
Life Sciences research has particular relevance since it has 
repercussions in the clinical practice (on both diagnosis and 
therapy) and, thus, on the occurrence of innovations. In this 
context, Laboratory Medicine operates at the frontiers of 
health care and research activities; this favours the knowledge 
of specific technical and scientific needs, facilitating 
translational research rather than in other areas (1). However, 
the development of innovative solutions transferable to 
the market is characterized by the need for important 
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investments (2), a very long “time to market” and specific 
economic-managerial skills. As a consequence, researchers are 
often unable to transfer their research results into products 
ready for the market (3). Nevertheless, the technology 
transfer process has become crucial for the universities that 
intend to give socio-economic, as well as cultural, value to 
the results of academic research. A vehicle for this type of 
entrepreneurial initiative are public research spin-offs, i.e., 
companies consisting mainly of university professors and 
researchers that base their activities on the know-how gained 
in the university. As reported in the Netval Report 2018 
(http://netval.it/), 1,373 public research spin-offs are present 
in Italy, and this trend is rapidly growing. Interestingly, about 
80% of the counted spin-offs have been established in the last 
10 years, 90.4% of which originated from the universities, 
and the remaining 9.5% came from other public research 
institutes (6.3% operate in the biomedical sector).
This paper provides the concrete evidence on the 
exploitation of the results obtained by KronosDNAsrl 
(KronosDNA), a biomedical SME, spin-off of University 
of Naples Federico II, specialized in molecular diagnostics 
activities in the field of human reproduction. KronosDNA 
has been founded by three female researchers, involved 
in scientific and translational research, with the mission 
to combine scientific progresses and biotechnological 
innovations into genetic tests that meet the need to 
optimize the diagnostic path of infertile couples. In this 
context, the One4Two® project was born and developed.
The purpose of this paper is to show and to contextualize 
the activities that have allowed KronosDNA to transfer its 
research results to the market.
The genetic tests in the diagnostic process of the infertile 
couple
During the last decades, there were a series of stunning 
advancements in reproductive medicine and laboratory 
medicine that essentially led these two fields to be 
inextricably related; laboratory medicine now plays an 
essential role in all stages of the reproductive process, 
starting from diagnostic approaches up to the choice of the 
most complex therapy (4,5).
To date, about 1 in 7 couples have trouble getting 
pregnant or sustaining a pregnancy (15% of couples 
trying for a child) and 7.4 million women (11.9%) have 
received fertility treatments in their lifetime (5). It has to be 
underlined that the conception requires the combined and 
precisely coordinated function of the reproductive system 
of both partners; as a consequence, the couple evaluation 
should be mandatory (5), while it is still unusual in the 
clinical practice (6). In this context, reproductive genetics 
has become even more important to support couples 
who are undergoing assisted reproductive technologies 
(ART) (Figure 1). However, genetic tests were considered 
ineffective (they identify only a few of the genetic variants 
related to infertility, compared to the advances reported 
in the literature) and inefficient (low detection rate, about 
10%) (5-7). Moreover, during the genetic counselling 
activity, a high degree of patients’ dissatisfaction emerged, 
which identified in the genetic test one of the major causes 
of “delay” in completing their entire diagnostic process (to 
date, infertile couples wait in average up to 9 months to 
have a diagnosis). 
One4Two: an integrated system designed to optimize the 
diagnostic process of the infertile couple
Taking into account these needs, KronosDNA has 
developed One4Two®, an integrated diagnostic system 
able to optimize the genetic diagnosis of infertile couples, 
looking for infertility cause and preventing further 
genetic alterations transmission. It is based on the next 
generation sequencing (NGS), a disruptive method able 
to simultaneously analyse millions of DNA fragments in 
parallel at very high speeds and specificities; however, it 
should be noted that bioinformatics skills are required for 
data interpretation specifications, which often represents the 
actual bottleneck of NGS-based procedures and the main 
limitation to their widespread distribution (8). In order to 
facilitate the routine use of One4Two®, KronosDNA has 
designed a dedicated algorithm for the interpretation of 
data to solve current data management problems.
Ultimately, the combination of the innovative laboratory 
protocol and the diagnostic algorithm makes it possible to 
make genetic diagnosis more efficient (Figure 2).
Methods
In this session the methods used by KronosDNA to evaluate 
the feasibility of One4Two® are reported. The objective was 
not only to evaluate One4Two from a technological point 
of view, but even highlight the steps required to introduce 
it on the market. Ethics Approval was not required since 
market and technical analyses were carried out for this 
study. For the validation procedure (unpublished data) 
patients gave their informed consent to the use of their 
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Infertile couple: Failure to achieve a clinical 
pregnancy after 12 months of regular unprotected 
sexual intercourse
Specialist examination + biochemical 
and instrumental analysis
Success of clinical 
pregnancy (20%)
Failure of clinical
pregnancy
(45%)
Genetic test for
transmittable
diseases
Assisted 
reproductive 
technologies
Only one test 
Cost: 1,400 €
5 working days
Current tests for infertility 
• Several genetic tests for 
diagnosis + genetic test 
for transmittable diseases 
• Average cost 2,500 € 
• Average time: 9 months
Diagnosis
(65%)
No diagnosis
(35%)
Figure 1 The current infertility diagnosis process is a long-lasting and exhausting process for the couple which, to determine the causes of 
infertility, has to carry out a series of specialist examinations, and biochemical and instrumental analyses. Nevertheless, a successful diagnosis 
is achieved only in about 65% of the cases. To the remaining undiagnosed 35%, a series of genetic tests are prescribed, since several factors 
related to infertility have a genetic origin (i.e., chromosomal aberrations or single gene variants) and genetic diseases could have infertility 
as side-effect (i.e., phenotypes with multifactorial inheritance). Furthermore, all couples undergoing medically ART are required to carry 
out genetic tests to identify the most common genetic diseases that can be transmitted to their offspring. The traditional genetic diagnostic 
path (in orange in the figure) involves several series of tests with high costs and long diagnostic times (up to 9 months), as the couple must 
undergo several blood tests, often going to different laboratories, and the laboratories perform a dedicated analysis for each genetic disease, 
which requires different techniques and specialized laboratory personnel. Using One4Two® (in green in the figure) the couple must have 
only one blood sample withdrawal and all the results are obtained through a single laboratory protocol; the optimization of the entire 
diagnostic procedure is highlighted by the reduction of costs and times. ART, assisted reproductive technologies.
DNA in anonymous form.
Methods used for technical feasibility assessing 
The technical feasibility study focused on the validation 
of the performances obtained with the prototype, starting 
from the laboratory procedures (sample preparation 
and integration with NGS) up to the analysis pipeline 
(processing time and reporting functionality). At this 
scope, KronosDNA used One4Two® to analyze in blind 
70 DNA samples (48 for intralaboratory validation and 22 
for interlaboratory validation) previously analysed with 
traditional lab methods (for instance Reverse Dot-Blot, 
Real-Time PCR, etc.) (unpublished data). 
Furthermore, following a user-centred design approach, 
KronosDNA has also collected feedback from laboratory 
staff regarding the performance and characteristics of the 
laboratory procedures, in order to achieve the highest 
standards compliant with European guidelines for the 
management of genetic tests with NGS (9). For the same 
reason, feedbacks from gynaecologists were collected to test 
their satisfaction level.
Methods used for technology transfer process management 
The strategic planning
Strategic planning, as a medium-long term forecasting 
method, has allowed to track the management of the 
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Couple Blood
samples
LAB
One4Two reagents 
kit added to blood 
samples
NGS One4Tvo 
Software
The gynaecologist 
receives one 
comprehensive report
Genetic causes of infertility in 5 days
Figure 2 One4Two® flowchart. One4Two® requires a single blood sample for each member of the couple from which the DNA to be 
analyzed is extracted. Through a routine laboratory protocol, specific molecular probes react with the DNA of each patient to enrich a 
specific set of genes to be sequenced, thus highlighting the presence of possible alterations in the genes implicated in infertility and in those 
responsible for some of the most frequent hereditary genetic diseases. Data analysis is performed by a software, comparing the data of each 
patient with a reference control sample. All the information about the genes analyzed (carrier status for each individual, infertility causes 
and the risk of transmitting genetic pathologies to the offspring) are summarized in a single report for the couple by a dedicated algorithm. 
NGS, next generation sequencing.
Table 1 Evaluation of the state of the organization
Key elements Declination
Company mission Combine scientific processes and biotechnological innovations in genetic tests that meet the need to 
optimize the diagnostic path of infertile couples
Strategic targets Development and commercialization of genetic tests for couple infertility that differ from those currently in 
use in terms of efficiency (due to the innovative laboratory methods used), and of effectiveness (due to the 
diagnostic algorithm designed for data management)
Organizational structure Informal and flat
Financial resources Grant and own capital
Human resources MD, PhD specialist in molecular diagnostics
MD, PhD specialist in gene sequencing
Biotechnologist, PhD specialist in human reproduction
Expertise Technical-scientific skills in molecular diagnostics and reproductive medicine
innovation focusing on strategic objectives and resource 
management, defining policies, and assessing risks/
opportunities. Starting from the assessment of the state 
of art (stage of development of the prototype, human and 
financial resources, skills present in KronosDNA, strengths 
and weaknesses), it was possible to identify the actions 
required and define the strategic objectives. The evaluation 
of the state of the organization (Table 1), the trend analysis 
(Table 2) and the stakeholder matrix (Figure 3) were carried 
out. The intersection of these data with the internal and 
external analysis provided the basis for the Strenghts, 
Weaknesses, Opportunities and Threats (SWOT) analysis 
(Figure 4).
The strategic control systems
The application of strategic control systems leads to improve 
corporate performance, so it is important to implement 
its use also in spin-off companies such as KronosDNA. In 
this case, the Balanced Score Card (BSC) is a particularly 
useful  tool in measuring performance (Figure 5 ) , 
since it allows to align strategy, objectives and activities 
starting from the mission and from the vision. Through a 
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Table 2 The trend analysis
Trend Notes
Probability (from 
1-low to 5-high)
Impact (from 
1-low to 5-high)
Stable probability of infertility 1 couple out of 5 (75 million) 5 5
1,200 medical experts in the field – 5 5
Almost 85% of infertile couples undergo genetic tests – 5 5
No multigenetic panel for infertility is currently on the 
market
There are panels for oncology and inherited 
pathologies (i.e., cardiomyopathy). Some 
projects are ongoing for infertility
1 5
About 150 laboratories in Italy have NGS facility NGS is diffusing fast in clinical practice 5 5
Cost of genetic tests is decreasing Thanks to the reduced cost of reagents 5 1
Cultural changes towards proactive health system Patients are more informed (awareness 
campaigns, independent)
5 5
Increasing attention to patients experience Source: Future of Health report, PSFK 5 5
Increasing use of genomic data for tailored plans Source: Future of Health report, PSFK 5 5
Creation of Consumer platforms 55% of technological innovations in life 
sciences
5 5
92% of physicians recognizes the utility of AI and 
cloud computing for data analysis 
– 5 5
The trend analysis, based on the observation of the evolution of specific market trends related to infertility and genetic tests, has allowed 
to map the trends and to obtain strong insights that have been used to guide in the strategic choices. AI, artificial intelligence; NGS, next 
generation sequencing.
Figure 3 The stakeholder matrix.
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Highly skilled team, with bioinformatics and medical competences
Growing demand for infertility screening
Well defined customer and value chain
Development of new tailored medical plan based on genetic data
NGS diffusion is growing among fertility labs
Low economic resources
Low competences in marketing and management
Distribution channels only partially active
Supply chain defined but still not contractualised
Diffusion of genetic panels specifically set for single pathology
The culture of multi-pathology screening is still to be disseminated
Strong competition on fertility screening
Single genetic tests price is lowering
Weaknesses
Threats
Technology and team highly recognized by the scientific community
Price and analysis time is drastically better than competitors
Ability to attract private funds
Strenghts
Opportunities
Figure 4 The SWOT analysis. SWOT, Strenghts, Weaknesses, Opportunities and Threats. 
Figure 5 The Balanced Score Card (BSC). 
top-down process, with the aim of organizing the multiple 
activities of all of the company, it provides the complete 
picture of operating activities, facilitating communication 
and understanding in relation to the defined objectives.
Market analysis and business assessment
To validate the business model and the price strategy, the 
current market for infertility tests was investigated by 
surveying the intended customers (genetic analysis labs). A 
Annals of Translational Medicine, Vol 8, No 6 March 2020 Page 7 of 13
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(6):353 | http://dx.doi.org/10.21037/atm.2020.02.61
cost-benefit analysis, including the definition of the business 
case, was also included to assess the economic benefits for 
both laboratories and the infertile couples.
To better define the product ecosystem in-depth 
market analysis was also assessed, including the current 
and prospect competitors, as well as a Political, Economic, 
Socio-cultural, Technological,  Environmental  and Legal 
(PESTEL) analysis (Figure 6). In particular, the different 
national health systems, regulations linked to genetic tests, 
economic subsidies, public/private nature of the laboratories 
were taken into account.
Results
Results obtained from the assessment of technical feasibility
The results obtained by One4Two® from the validation of 
both the laboratory procedures and data interpretation are 
perfectly comparable with those obtained with traditional 
methods, without false positives nor false negatives, 
thus reaching TRL 9 (Technology Readiness Level) and 
providing 100% accuracy. 
From the analysis of the utility and satisfaction 
questionnaires, we obtained the feedbacks of the consulted 
focus groups. In particular, the laboratories gave very 
positive feedback on the efficiency of the workflow, and 
the gynaecologists showed satisfaction for the diagnostic 
effectiveness.
Results obtained from the evaluation of the management 
of the technology transfer process
The analysis of the state of the art has shown that 
KronosDNA’s mission and objectives were well defined, as 
well as the technical-scientific skills to develop and validate 
One4Two; financial resources to purchase laboratory 
reagents and to integrate the skills were instead necessary.
Trend analysis has allowed us to investigate both the 
trends related to infertility and those related to genetic 
tests. It turned out that infertility permanently involves a 
high number of couples, who undergo specialized care (the 
number of specialists in the field of reproduction is limited) 
and specific genetic tests. At the moment there are no 
genetic panels for infertility in NGS, but that the use of this 
technology has a rapid diffusion as it has a positive impact 
on the entire diagnostic process.
Stakeholder analysis was useful for identifying: (I) 
reproduction specialists as the subjects to be involved 
in evaluating the completeness of the genetic panel; (II) 
biotechnology companies with technological affinity, but 
Possible raise of COGS could
Possible raise of new competitor
Certifications required to go to
market is currently changing in
Europe and could change in
other countries
Freedom to operate could be
limited to certain countries
technologies
R&D expenses could raise too much
Reliability could be below existing
methods
affect pricing strategy
Taxes could raise
Cost of personnel could raise
Scale-up of production
volumes could lower final
Legislation concerning fertility test could
Politics
Economy
Social
Technology
Environment
Legal
Trends see a decrease in the One4Two helps to reduce the 
number of fertility tests which
have disposable parts
number of children per couple
Social pressure can facilitate
National Reimbursement
change
Some countries could limit the use of
genetic tests due to data management
concerns
Legislation concerning patents could
change
price
Figure 6 The PESTEL analysis. COGS, cost of goods sold; PESTEL, Political, Economic, Socio-cultural, Technological,  Environmental 
and Legal.
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different diagnostic purposes for collecting contextual 
information; and (III), finally, laboratories and patients in 
the external review of effectiveness and efficiency. 
Taking into consideration the SWOT analysis, it was 
possible to identify the factors that can create (green) and 
destroy (red) the company value, and all the factors to be 
kept under control (yellow) (Figure 7).
The strategic control  systems implemented by 
KronosDNA have been defined according to the control 
levers devised by Robert Simons (10). The values of 
KronosDNA were formalized in the Mission (“Combining 
scientific progress and biotechnological innovations in 
genetic tests that respond to the need to optimize the 
diagnostic path of infertile couples”) and in the corporate 
Creed (“Dealing with motherhood is a qualifying way of 
thinking about a model of growth and development”). 
Mission and corporate Creed are reported in the 
introductory/presentation section of the business plan, in 
the summary documents presented to the stakeholders or to 
potential investors. The positivity expressed has supported 
the definition of the strategy and has motivated the team, 
towards a participatory approach by decisively resolving the 
external environmental difficulties.
The Vision (“To create specific diagnostic tools for reproductive 
medicine”) clearly states that the strategic positioning of 
the company is a biotech company engaged in the R&D 
of diagnostic genetic tests in the field of reproductive 
medicine, but not in screening or predisposition genetic 
tests. This has defined the presence of limits to the strategic 
opportunities that can be pursued (indeed, from the analysis 
of the trends there is a growing presence on the market of 
multi-gene tests for screening or predisposition), avoiding 
pursuing objectives that are not consistent with the 
company’s mission and with the code of professional ethics, 
to which the team refers (limits to behaviour).
The Diagnostic Control system was based on the 
feedback mechanism, considering as output One4Two®’s 
validation and introduction on the market, and as additional 
performance indicators the ability to attract grants for 
technology transfer activity, and to produce scientific 
publications. This allowed to support the team in future 
strategic decisions (allocation of resources in marketing and 
communication), encouraging and motivating towards the 
scale-up phase.
Finally, the coaching program, which KronosDNA 
benefited as winner of Horizon2020 PMI instrument, 
was identified for the interactive control system. This 
program focused on identifying strategic key factors for the 
internationalization (analysis of European legislation and 
regulations beyond Italian regulation) and on the inclusion 
Focus the communication campaign on:
1) Reduction of time (patients, labs and specialists)
2) Optimization of the workflow (labs)
3) Optimization of the report (specialists)
Solid scientific basis and high detection rate 
(>95%)
360° evaluation on infertility, hereditary  
pathologies and pharmacogenomics
The weakness of competitors (tests conducted 
with inefficient and ineffective traditional  
methods) and the positive trend towards proactive 
culture, the use of genomic data, attention to the  
customer experience to activate marketing 
strategies and an effective communication 
campaign.
Expand the range of subjects to be offered 
analysis, including gamete donors for 
heterologous fertilization
The narrow but well-defined market of NGS 
laboratories can be “controlled” and more 
easily achieved
S-O
S-T
O-W
T-W
Figure 7 The results of the SWOT analysis. SWOT, Strengths, Weaknesses, Opportunities and Threats.
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of new strategic choices (implementation of clinical 
competence to optimize patients’ governance).
Moreover, during this stage the current market for 
infertility test was investigated; it is forecasted to have 
positive trend, due to the declining fertility rates across 
the globe, the increasing of the age for the first-time 
pregnancy and the introduction of user-friendly fertility 
monitors which facilitate the whole pregnancy path for the 
couple (11-13). The analysis of the competitors was also 
carried out, and it turned out that the main competitors of 
KronosDNA are to be considered companies that already 
produce diagnostic kits for NGS. Their advantages are the 
consolidated distribution and high expertise in the sector, 
but they lack specific know-how on infertility tests and 
interpretation of data for diagnostic purposes, as proved 
by the fact that often they don’t produce bioinformatics 
pipeline software for genetic analysis. The global market is 
dominated by a few top producers (i.e., Illumina, Thermo 
Fisher Scientific, and Pacific Biosciences) which produce 
both NGS instruments and kits for different genetic test.
The Cost Benefit Analysis quantified the economic 
benefits and costs for both laboratories and the infertile 
couples: One4Two® allows to complete the entire diagnostic 
process in 1–2 months (of which only 5 days for the genetic 
test at the cost of €1,400 per couple) and to reduce the time 
to pregnancy (from 9 to 1–2 months). The detection of 
average prices applied on the market for similar diagnostic 
kit types has established that for the entire diagnostic 
journey today the couple spends at least €2,500 (€1,250 per 
patient); using One4Two®, the final price for the couple will 
be €1,400 (€700 per patient).
Discussion 
Since its foundation (June 2016), KronosDNA has mainly 
carried out research and development activities aimed at the 
development and the commercialization of genetic tests that 
differed in terms of efficiency (due to innovative laboratory 
methods) and effectiveness (due to a diagnostic pipeline). 
One4Two® is radically changing the current diagnostic 
approach from the direct search for known infertility-
related genetic mutations (each requiring a dedicated test) 
to a comprehensive DNA scanning able to highlight all the 
mutations; it allows to reduce the analytical times and costs, 
has a positive impact on the entire diagnostic process. 
One4Two® is poised to provide the following unique 
benefits to the end-users and indirect beneficiaries of its 
adoption: 
 Genetic laboratories (customers) will add to their 
test portfolio an innovative system, which will make 
them save costs (drastically reducing the workload for 
interpreting data) and increase their customer base.
 Infertile couples (end users and main beneficiaries) 
will have the complete genetic characterization in 
5 days and at an estimated cost of €1,400 per couple 
(based on our preliminary interviews with labs and 
gynaecologists).
 Gynaecologists (main drivers) will receive a unique 
and complete diagnostic report, easy to interpret to 
define the diagnosis, the most suitable therapy, and 
the indication for the antenatal diagnosis.
KronosDNA was born with an informal and flat 
organizational structure, focused on the production of 
a single innovative product placed in a defined market 
segment. The founders dealt directly with the most 
important strategic choices including among others 
capital management. The strategy was not the result of 
an explicit design, but the sum of actions that followed 
one after another according to a logical thread inspired by 
the corporate aims. KronosDNA used programming and 
control tools oriented to multidimensional measurement 
in the short term. In particular, they are based on a system 
with low centrality, fed both by monetary indicators (e.g., 
income statement, price-balance of reagents) and non- 
monetary indicators (e.g., intra and extra-lab validations) 
that suit dynamic systems that are being defined and 
developed.
KronosDNA’s activities were carried out thanks to 
the grant destined to the technological transfer that 
KronosDNA was able to attract and its own capital. 
One4Two® was introduced on a benchmark market in 
February 2019.
The role of the ecosystem of innovation and the 
initiatives that the universities have adopted to support 
entrepreneurship, by increasing the propensity to create 
business (14-17), have been essential in the first phase of 
development of One4Two®. 
The grants and training courses received allowed the 
development of the prototype and the planning of a strategy 
aimed at realizing the project in an academic context and 
bringing innovation to clinical practice. The milestones of 
KronosDNA has been reconstructed in Figure 8.
Among the key elements for the birth and development 
of KronosDNA there is certainly the team: the union of 
their knowledge, skills and experience has allowed to obtain 
the results of the research that led to the development of 
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One4Two®. Unlike the undisputed statistical evidence of 
a lower quantitative presence of female business owners 
(18,19), never exceeding 18% of the startup population (20), 
KronosDNA was founded and managed by an exclusively 
female team. Moreover, some studies report that the 
innovative female-driven startups, founded in recent years, 
have underperformed those of men (21). However, this has 
not been confirmed for those, based on innovative scientific 
or technological initiatives (22); where competence and 
knowledge are factors on which to build the corporate value 
proposition and the gender variable has no impact on business 
performance (23). In agreement with what emerged from 
the exploratory survey by Demartini and Marchegiani (24), 
the critical success factors for KronosDNA, in addition 
to knowledge and skills, are participatory leadership that 
promoted integrated thinking and participatory processes of 
co-creation.
However, it is certainly clear that the availability of 
financial resources plays a central role in the competitive 
growth of a spin-off (25). In the initial phases, the financing 
with own capital and the grants obtained from the 
participation in national and international competitions 
for start-ups allowed to advance the research up to the 
validation of One4Two®. Thanks to the latest grant 
received by the European Commission under the H2020-
SME Instrument program, it will be possible to establish 
marketing and communication activities for the launch of 
One4Two® on a broader market. Having the requisites to 
participate and obtain a European grant was important, 
above all as an internationalization opportunity in order to 
build a network and an international reputation.
In this path, it is clear that the phases that go from the 
moment of invention to that of first prototyping are those 
that require financing (26). Some universities have started 
experimental initiatives in this field using their own funds, 
but this approach seems not to be sustainable at the system 
Figure 8 Milestones of KronosDNA from the generation of the idea until today. One4Two® was still in an embryonic state when it won one 
of the regional StartCup awards in 2015 and later the Special Mention on “female entrepreneurship” at the National Innovation Award (http://
www.pnicube.it/). The idea was consolidated thanks to the participation in BioUpper, a training course at PoliHub (https://www.polihub.
it), the incubator of the Politecnico di Milano, and EIT-Health Innostars program (https://www.eithealth.eu/innostars) during which the 
team started planning a strategy and understood the importance of setting up a spin-off to be able to carry out the project and place the 
innovation in the clinical practise.
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level. The experience of many universities belonging 
to European countries has demonstrated the need and 
effectiveness of these initiatives (27). It is, therefore, hoped 
that funding will be made available given the crucial role 
played by universities as a forge for the development of new 
spin-offs. 
Conclusions
Promoting the “third mission” means promoting the 
enhancement and use of knowledge in order to contribute 
to the development of the society through the development 
of new business realities. To achieve this goal, it is necessary 
to involve teaching staff, researchers, PhD students and 
also students (28,29), and to strengthen the Technology 
Transfer Offices. In recent years, some universities 
have adopted measures to support entrepreneurship by 
increasing the propensity to create business, promoting the 
creation of ad hoc support contexts for business start-ups 
(15,16). Currently, it has been already planned, and in some 
universities is already taking place, to implement doctoral 
courses with teachings on the theme of the technology 
transfer. Starting from its own experience, the KronosDNA 
team believes that it is a very important activity and suggests 
its extension also for undergraduate courses, starting 
from those of the STEM sectors. The coordination of 
these courses with the Technology Transfer Offices of the 
university would be desirable.
M u c h  o f  e m p i r i c a l  r e s e a r c h  i n  u n i v e r s i t y 
entrepreneurship is devoted to the emergence of research 
spin-offs (30,31), while it is not so explored the mode, not 
only financial, for their accompaniment to consolidation. In 
the case of KronosDNA, in which the team is characterized 
by mainly scientific know-how, the Technology Transfer 
Office has played an important role above all in the early 
stages of setting up the spin-off and management of 
intellectual property (32). We reiterate the need to support 
activities to support company consolidation through 
legal, economic, mentoring, etc. (33). Strengthening 
the Technology Transfer Offices of Universities and 
Research Institutions means, looking at international 
experience, endowing them with profiles featured by high 
professionalism, multidisciplinary, and multi-sectorial skills 
in order to facilitate contacts between the academic world 
and entrepreneurship, and consolidate the entrepreneurial 
activity born on the basis of public research. Beyond the 
direct economic and employment impact, these are highly 
knowledge-based companies that, with their inclusion in 
the productive chains of the respective territories, may 
contribute to fueling their competitiveness and dynamism.
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